drugset / Trial / NCT06445803
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Non-randomizedSequentialOpen-labelTreatment
Summary
This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
Timeline
- Start
- 2024-05-31
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KQ-2002 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | KQ-2002 CAR-T cells | Cell therapy | 5e+06 cells/kg | — |